Holy Cross 9th Annual Winter Oncology Symposium

https://www.hconcologysymposium.com/

 

Holy Cross 9th Annual Winter Oncology Symposium
Avatar

Re-Challenging with Immunotherapy in Metastatic NSCLC: Would Retreatment with anti-PD-L1 Develop a Recurrent Side Effect?

By Holy Cross 9th Annual Winter Oncology Symposium FEATURING Ibiayi Dagogo-Jack
By Holy Cross 9th Annual Winter Oncology Symposium FEATURING Ibiayi Dagogo-Jack
0 views
May 15, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

17:33
AstraZeneca Oncology

First-line Maintenance Therapy for BRCAm Advanced Ovarian Cancer Fol…

Feat. S. Lewin
Lung Cancers
23:25
Holy Cross 9th Annual Winter Oncology Symposium

The Use of EBUS in Early Detection of Lung Cancers

Feat. S. Kosseifi
16:59
Holy Cross 9th Annual Winter Oncology Symposium

PD-L1 Monotherapy vs. PD-L1+Chemo Combination Therapy in Metastatic …

Feat. I. Dagogo-Jack
15:56
Holy Cross 9th Annual Winter Oncology Symposium

Pneumonitis, Thyroiditis, Myocarditis, and Hepatitis as Side Effects…

Feat. I. Dagogo-Jack
05:39
Holy Cross 9th Annual Winter Oncology Symposium

Re-Challenging with Immunotherapy in Metastatic NSCLC: Would Retreat…

Feat. I. Dagogo-Jack
23:13
Holy Cross 9th Annual Winter Oncology Symposium

Targeted Therapy and Related Side Effects in Advanced NSCLC

Feat. L. Raez
15:04
Holy Cross 9th Annual Winter Oncology Symposium

Genomic Profiling for Metastatic NSCLC

Feat. D. Drew
17:27
Holy Cross 9th Annual Winter Oncology Symposium

Stereotactic Radiotherapy in Stage I Lung Cancer

Feat. L. Goyal, V. Patel